Skip to main content

View full-text article in PMC

. 2020 May 1;145:106517. doi: 10.1016/j.cie.2020.106517

Table 4.

The comprehensive evaluations of four medicines.

Medicine	BPA
Ribavirin	$m (H_{1}) = 0.23, m (H_{2}) = 0.19, m (H_{4}) = 0.1, m (H_{3}, H_{4}) = 0.08, m (H) = 0.4$
Lianhuaqingwen Capsules	$m (H_{1}) = 0.1, m (H_{2}) = 0.09, m (H_{3}) = 0.2, m (H_{4}) = 0.15, m (H_{3}, H_{4}) = 0.06, m (H) = 0.4$
Lopinavir/Ritonavir	$m (H_{2}) = 0.08, m (H_{3}) = 0.4, m (H_{4}) = 0.12, m (H_{2}, H_{3}, H_{4}) = 0.03, m (H) = 0.37$
Remdesivir	$m (H_{2}) = 0.07, m (H_{3}) = 0.18, m (H_{4}) = 0.26, m (H_{3}, H_{4}) = 0.12, m (H) = 0.37$